Let’s deliver
life-changing therapies together
With decades of experience and unmatched technical expertise, OXB’s CDMO services power some of the world’s leading cell and gene therapy programs, bringing life-changing treatments to patients worldwide.
OXB is a global quality and innovation-led cell and gene therapy CDMO, providing end-to-end services to clients from pre-clinical through to commercial launch
Our expertise spans lentivirus, AAV, and other viral vectors, delivering safe, scalable, and high-quality solutions that help bring life-changing therapies to patients worldwide.
0+
Total client programmes
0+
GMP batches
0+
Regulatory submissions
OXB’s CDMO solutions
Ways to work with us
There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.
Platform project
For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process.
Custom solution
For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate.
Tech-transfer
For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale and/or long-term manufacture.
Our clients
OXB’s viral vectors
We have extensive end-to-end capabilities in lentivirus and AAV vectors, as well as adenovirus systems and can help you design, develop, manufacture and deliver the life-changing medicines of tomorrow.
30 years of lentiviral vector manufacturing
As a pioneer in lentiviral vector technology, OXB brings three decades of proven experience to the development and manufacturing of lentiviral vectors for cell and gene therapies. Now a global CDMO, we support partners from early development through to commercialisation.
Access innovative technology and unmatched expertise
With decades of leadership in lentiviral vector production, OXB gives clients access to some of the industry’s most experienced scientific minds. Our commitment to continuous innovation ensures clients benefit from the latest advancements in viral vector manufacturing to deliver best in class cell and gene therapies.
Receive comprehensive regulatory support through to commercialisation
OXB provides end-to-end regulatory support, guiding clients from preclinical development through to commercial launch. We have successfully supported multiple IND and MAA submissions, and maintain a Drug Master File (DMF) with the FDA, reinforcing our credibility as a trusted global CDMO partner.
Leverage local manufacturing with a global footprint
With harmonised lentiviral vector manufacturing processes across our UK, US, and European facilities, OXB enables efficient, scalable production from 50L to 1000L, close to your clinical or commercial markets. Our global footprint ensures flexibility, consistency, and speed—wherever you are.
Accelerated AAV manufacturing with industry-leading performance
OXB delivers fast, flexible, and high-performance AAV manufacturing solutions to support advanced therapy developers worldwide. Our proprietary inAAVate™ platform can deliver GMP AAV in as little as 7 months and consistently achieves high titres and market leading full-to-empty capsid ratios.
Reach GMP in as little as 7 months
By leveraging the inAAVate™ plug-and-play platform process, the need for excessive process development is eliminated, allowing clients to reach GMP in as little as 7 months.
Maximise commercial viability with more doses per batch
By continually developing innovative technologies, OXB clients can now achieve titres of 1.5E+17vgs from a 500L bioreactor, with 90% full capsids, delivering cost efficiencies through more doses per batch.
Effectively manage budgets and milestones
Our flexible delivery and commercial models ensure clients can effectively manage budgets in line with funding milestones and decision points.
Adenovirus manufacturing expertise proven at scale
OXB is an experienced partner for adenovirus development and manufacturing, most famously demonstrated during the COVID-19 pandemic, when OXB manufactured over 100 million doses of the Oxford–AstraZeneca COVID-19 vaccine.
Proven global delivery
OXB has manufactured adenoviral vectors at a scale few others can match, contributing to millions of doses supplied worldwide.
Flexible end-to-end CDMO model
Streamlined development through proven platform processes minimizes risk, accelerates timelines, and cuts expenses.
Advanced GMP infrastructure
OXB has GMP facilities in the UK, Europe and USA to meet the geographical needs of our clients and ensure they benefit from cutting-edge technology and secure global supply chains.
Broad viral vector expertise and infrastructure
Alongside lentivirus, AAV, and adenovirus, OXB also has the expertise and infrastructure to support development and manufacturing of other viral vectors, enabling clients to explore alternative approaches for gene therapy, oncolytic therapies, and vaccines.
MVA (Modified Vaccinia Ankara) vectors
MVA has become an important viral backbone for immuno-oncology and infectious disease vaccines, thanks to its ability to elicit strong immune responses and its excellent safety profile.
Other poxvirus vectors
Building on our MVA capabilities, OXB can also apply its knowledge to other poxvirus-based vectors, which are increasingly being explored for therapeutic vaccines and novel immunotherapies.
Ways to work with us
There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.
Latest news
Preliminary results for the year ended 31 December 2025
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved: Revenue growth of 33% to £170.9 million (CC) (FY 2024: £128.8……
View details >OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms
Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into……
View details >OXB announces date for Capital Markets Day and participation in upcoming investor conferences
Oxford, UK – 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the date of its Capital Markets Day and participation at upcoming investor conferences. Capital Markets Day OXB will hold……
View details >OXB’s resource library
View and download our resources.
Subscribe to receive OXB's latest news, events and insights
